The UltIMMa trials of risankizumab demonstrated superior efficacy in treating moderate-to-sever plaque psoriasis compared to ustekinumab. ... read more

Acne vulgaris is the most common skin condition treated by dermatologists. Approximately 50 million people in ... read more

A research poster analyzing data from a study of halobetasol propionate 0.01% and tazarotene 0.045% lotion ... read more

An analysis of data from a trial of halobetasol and tazarotene lotion in patients with moderate-to-severe ... read more

Onychomycosis is a common nail disorder caused by dermatophytes, non-dermatophytes, and yeasts and other molds. It ... read more

There are currently no FDA-approved treatments for molluscum contagiosum, even though it is a fairly common ... read more

The phase 2 WART-203 trial evaluated the efficacy and safety of a 45% hydrogen peroxide solution ... read more

On Monday, November 12, 2018, the US Department of Health and Human Services will announce the ... read more